microRNA involvement in hepatocellular carcinoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 500-521

  Negrini, Massimo ^a   Gramantieri, Laura ^b   Sabbioni, Silvia ^a   Croce, Carlo M ^a,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Diagnosis; Hepatocellular carcinoma; microRNA; Therapy

Indexed keywords

AMINOTRANSFERASE; ANTAGOMIR 17 5 P; ANTI MIRNA OLIGONUCLEOTIDE; ANTINEOPLASTIC AGENT; BETA CATENIN; BIM PROTEIN; CHOLESTEROL BOUND OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; LNA MODIFIED OLIGONUCLEOTIDE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 122; MICRORNA 199; MICRORNA 21; MICRORNA 221; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL BLOOD LEVEL; DNA BINDING; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ENZYME INDUCTION; FOLLOW UP; GENE DELETION; GENE INACTIVATION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; LIPID METABOLISM; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; SIDE EFFECT; TUMOR MICROENVIRONMENT;

EID: 79959288902     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796011037     Document Type: Article

References (350)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
2. Perz, J. F.; Armstrong, G. L.; Farrington, L. A.; Hutin, Y. J.; Bell, B. P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol., 2006, 45(4), 529-538.
3. Rebouissou, S.; Bioulac-Sage, P.; Zucman-Rossi, J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J. Hepatol., 2008, 48(1), 163-170.
4. Bruix, J.; Sherman, M. Management of hepatocellular carcinoma. Hepatology, 2005, 42(5), 1208-1236.
5. Sangiovanni, A.; Del Ninno, E.; Fasani, P.; De Fazio, C.; Ronchi, G.; Romeo, R.; Morabito, A.; De Franchis, R.; Colombo, M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 2004, 126(4), 1005-1014.
6. Villanueva, A.; Toffanin, S.; Llovet, J. M. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol., 2008, 20(4), 444-453.
7. Murakami, Y.; Yasuda, T.; Saigo, K.; Urashima, T.; Toyoda, H.; Okanoue, T.; Shimotohno, K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006, 25(17), 2537-2745.
8. Kutay, H.; Bai, S.; Datta, J.; Motiwala, T.; Pogribny, I.; Frankel, W.; Jacob, S. T.; Ghoshal, K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem., 2006, 99(3), 671-678.
9. Volinia, S.; Calin, G. A.; Liu, C. G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; Prueitt, R. L.; Yanaihara, N.; Lanza, G.; Scarpa, A.; Vecchione, A.; Negrini, M.; Harris, C. C.; Croce, C. M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA, 2006, 103(7), 2257-2561.
10. Gramantieri, L.; Ferracin, M.; Fornari, F.; Veronese, A.; Sabbioni, S.; Liu, C. G.; Calin, G. A.; Giovannini, C.; Ferrazzi, E.; Grazi, G. L.; Croce, C. M.; Bolondi, L.; Negrini, M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res., 2007, 67(13), 6092-6099.
11. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S. T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133(2), 647-658.
12. Scott, G. K.; Goga, A.; Bhaumik, D.; Berger, C. E.; Sullivan, C. S.; Benz, C. C. Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b. J. Biol. Chem., 2007, 282(2), 1479-1486.
13. Wong, Q. W.; Lung, R. W.; Law, P. T.; Lai, P. B.; Chan, K. Y.; To, K. F.; Wong, N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology, 2008, 135(1), 257-269.
14. Jiang, J.; Gusev, Y.; Aderca, I.; Mettler, T. A.; Nagorney, D. M.; Brackett, D. J.; Roberts, L. R.; Schmittgen, T. D. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res., 2008, 14(2), 419-427.
15. Ladeiro, Y.; Couchy, G.; Balabaud, C.; Bioulac-Sage, P.; Pelletier, L.; Rebouissou, S.; Zucman-Rossi, J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/ tumor suppressor gene mutations. Hepatology, 2008, 47(6), 1955-1963.
16. Huang, Q.; Gumireddy, K.; Schrier, M.; le Sage, C.; Nagel, R.; Nair, S.; Egan, D. A.; Li, A.; Huang, G.; Klein-Szanto, A. J.; Gimotty, P. A.; Katsaros, D.; Coukos, G.; Zhang, L.; Pure, E.; Agami, R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol., 2008, 10(2), 202-210.
17. Braconi, C.; Patel, T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology, 2008, 47(6), 1807-1809.
18. Lin, C. J.; Gong, H. Y.; Tseng, H. C.; Wang, W. L.; Wu, J. L. miR- 122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun., 2008, 375(3), 315-320.
19. Nam, E. J.; Yoon, H.; Kim, S. W.; Kim, H.; Kim, Y. T.; Kim, J. H.; Kim, J. W.; Kim, S. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res., 2008, 14(9), 2690-2695.
20. Lee, Y.; Samaco, R. C.; Gatchel, J. R.; Thaller, C.; Orr, H. T.; Zoghbi, H. Y. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat. Neurosci., 2008, 11(10), 1137-1139.
21. Datta, J.; Kutay, H.; Nasser, M. W.; Nuovo, G. J.; Wang, B.; Majumder, S.; Liu, C. G.; Volinia, S.; Croce, C. M.; Schmittgen, T. D.; Ghoshal, K.; Jacob, S. T. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res., 2008, 68(13), 5049-5058.
22. Varnholt, H.; Drebber, U.; Schulze, F.; Wedemeyer, I.; Schirmacher, P.; Dienes, H. P.; Odenthal, M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 2008, 47(4), 1223-1232.
23. Budhu, A.; Jia, H. L.; Forgues, M.; Liu, C. G.; Goldstein, D.; Lam, A.; Zanetti, K. A.; Ye, Q. H.; Qin, L. X.; Croce, C. M.; Tang, Z. Y.; Wang, X. W. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 2008, 47(3), 897-907.
24. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep., 2008, 9(6), 582-589.
25. Nagel, R.; le Sage, C.; Diosdado, B.; van der Waal, M.; Oude Vrielink, J. A.; Bolijn, A.; Meijer, G. A.; Agami, R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res., 2008, 68(14), 5795-5802.
26. Wang, Y.; Lee, A. T.; Ma, J. Z.; Wang, J.; Ren, J.; Yang, Y.; Tantoso, E.; Li, K. B.; Ooi, L. L.; Tan, P.; Lee, C. G. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J. Biol. Chem., 2008, 283(19), 13205-13215.
27. Bai, S.; Nasser, M. W.; Wang, B.; Hsu, S. H.; Datta, J.; Kutay, H.; Yadav, A.; Nuovo, G.; Kumar, P.; Ghoshal, K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem., 2009, 284(46), 32015-32027.
28. Coulouarn, C.; Factor, V. M.; Andersen, J. B.; Durkin, M. E.; Thorgeirsson, S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene, 2009, 28(40), 3526-3536.
29. Fornari, F.; Gramantieri, L.; Giovannini, C.; Veronese, A.; Ferracin, M.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Croce, C. M.; Tavolari, S.; Chieco, P.; Negrini, M.; Bolondi, L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 2009, 69(14), 5761-5767.
30. Tsai, W. C.; Hsu, P. W.; Lai, T. C.; Chau, G. Y.; Lin, C. W.; Chen, C. M.; Lin, C. D.; Liao, Y. L.; Wang, J. L.; Chau, Y. P.; Hsu, M. T.; Hsiao, M.; Huang, H. D.; Tsou, A. P. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 2009, 49(5), 1571-1582.
31. Zhang, R.; Wang, L.; Yu, G. R.; Zhang, X.; Yao, L. B.; Yang, A. G. MicroRNA-122 might be a double-edged sword in hepatocellular carcinoma. Hepatology, 2009, 50(4), 1322-1323.
32. Xia, H. F.; He, T. Z.; Liu, C. M.; Cui, Y.; Song, P. P.; Jin, X. H.; Ma, X. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol. Biochem., 2009, 23(4-6), 347-358.
33. Salvi, A.; Sabelli, C.; Moncini, S.; Venturin, M.; Arici, B.; Riva, P.; Portolani, N.; Giulini, S. M.; De Petro, G.; Barlati, S. MicroRNA- 23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J., 2009, 276(11), 2966-2982.
34. Ji, J.; Shi, J.; Budhu, A.; Yu, Z.; Forgues, M.; Roessler, S.; Ambs, S.; Chen, Y.; Meltzer, P. S.; Croce, C. M.; Qin, L. X.; Man, K.; Lo, C. M.; Lee, J.; Ng, I. O.; Fan, J.; Tang, Z. Y.; Sun, H. C.; Wang, X. W. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med., 2009, 361(15), 1437-47.
35. Ji, J.; Yamashita, T.; Budhu, A.; Forgues, M.; Jia, H. L.; Li, C.; Deng, C.; Wauthier, E.; Reid, L. M.; Ye, Q. H.; Qin, L. X.; Yang, W.; Wang, H. Y.; Tang, Z. Y.; Croce, C. M.; Wang, X. W. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology, 2009, 50(2), 472-480.
36. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137(6), 1005-1017.
37. Li, N.; Fu, H.; Tie, Y.; Hu, Z.; Kong, W.; Wu, Y.; Zheng, X. miR- 34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett., 2009, 275(1), 44-53.
38. Li, S.; Fu, H.; Wang, Y.; Tie, Y.; Xing, R.; Zhu, J.; Sun, Z.; Wei, L.; Zheng, X. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology, 2009, 49(4), 1194-1202.
39. Li, Y.; Tan, W.; Neo, T. W.; Aung, M. O.; Wasser, S.; Lim, S. G.; Tan, T. M. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci., 2009, 100(7), 1234-1242.
40. Xu, N.; Papagiannakopoulos, T.; Pan, G.; Thomson, J. A.; Kosik, K. S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell, 2009, 137(4), 647-658.
41. Su, H.; Yang, J. R.; Xu, T.; Huang, J.; Xu, L.; Yuan, Y.; Zhuang, S. M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res., 2009, 69(3), 1135-1142.
42. Liu, W. H.; Yeh, S. H.; Lu, C. C.; Yu, S. L.; Chen, H. Y.; Lin, C. Y.; Chen, D. S.; Chen, P. J. MicroRNA-18a prevents estrogen receptor- alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology, 2009, 136(2), 683-693.
43. Furuta, M.; Kozaki, K. I.; Tanaka, S.; Arii, S.; Imoto, I.; Inazawa, J. miR-124 and miR-203 are epigenetically silenced tumorsuppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 2010, 31(5), 766-776.
44. Ma, L.; Liu, J.; Shen, J.; Liu, L.; Wu, J.; Li, W.; Luo, J.; Chen, Q.; Qian, C. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol. Ther., 2010, 9(7), 554-561.
45. Ji, J.; Zhao, L.; Budhu, A.; Forgues, M.; Jia, H. L.; Qin, L. X.; Ye, Q. H.; Yu, J.; Shi, X.; Tang, Z. Y.; Wang, X. W. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J. Hepatol., 2010, 52(5), 690-697.
46. Shimizu, S.; Takehara, T.; Hikita, H.; Kodama, T.; Miyagi, T.; Hosui, A.; Tatsumi, T.; Ishida, H.; Noda, T.; Nagano, H.; Doki, Y.; Mori, M.; Hayashi, N. The let-7 family of microRNAs inhibits BclxL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol., 2010, 52(5), 698-704.
47. Xiong, Y.; Fang, J. H.; Yun, J. P.; Yang, J.; Zhang, Y.; Jia, W. H.; Zhuang, S. M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology, 2010, 51(3), 836-845.
48. Cheng, J.; Zhou, L.; Xie, Q. F.; Xie, H. Y.; Wei, X. Y.; Gao, F.; Xing, C. Y.; Xu, X.; Li, L. J.; Zheng, S. S. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics, 2010, 10(8), 1557-1572.
49. Lee, E. K.; Lee, M. J.; Abdelmohsen, K.; Kim, W.; Kim, M. M.; Srikantan, S.; Martindale, J. L.; Hutchinson, E. R.; Kim, H. H.; Marasa, B. S.; Selimyan, R.; Egan, J. M.; Smith, S. R.; Fried, S. K.; Gorospe, M. miR-130 suppresses adipogenesis by inhibiting PPAR{gamma} expression. Mol. Cell Biol., 2010.
50. Wu, Q.; Jin, H.; Yang, Z.; Luo, G.; Lu, Y.; Li, K.; Ren, G.; Su, T.; Pan, Y.; Feng, B.; Xue, Z.; Wang, X.; Fan, D. MiR-150 promotes gastric cancer proliferation by negatively regulating the proapoptotic gene EGR2. Biochem. Biophys. Res. Commun., 2010, 392(3), 340-345.
51. Fornari, F.; Milazzo, M.; Chieco, P.; Negrini, M.; Calin, G. A.; Grazi, G. L.; Pollutri, D.; Croce, C. M.; Bolondi, L.; Gramantieri, L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res., 2010, 70(12), 5184-5193.
52. Gao, P.; Chak-Lui Wong, C.; Kwok-Kwan Tung, E.; Man-Fong Lee, J.; Wong, C. M; Oi-Lin Ng, I. Deregulation of microRNA expression occurs early and accumulates in early stages of HBVassociated multistep hepatocarcinogenesis. J. Hepatol., 2010.
53. Shen, Q.; Cicinnati, V. R.; Zhang, X.; Iacob, S.; Weber, F.; Sotiropoulos, G. C.; Radtke, A.; Lu, M.; Paul, A.; Gerken, G.; Beckebaum, S. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol. Cancer, 2010, 9, 227.
54. Xia, H.; Ng, S. S.; Jiang, S.; Cheung, W. K.; Sze, J.; Bian, X. W.; Kung, H. F.; Lin, M. C. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem. Biophys. Res. Commun., 2010, 391(1), 535-541.
55. Liu, A. M.; Poon, R. T.; Luk, J. M. MicroRNA-375 targets Hipposignaling effector YAP in liver cancer and inhibits tumor properties. Biochem. Biophys. Res. Commun., 2010, 394(3), 623-627.
56. Yang, L.; Ma, Z.; Wang, D.; Zhao, W.; Chen, L.; Wang, G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol. Ther., 2010, 9(10), 803-808.
57. Yang, F.; Yin, Y.; Wang, F.; Wang, Y.; Zhang, L.; Tang, Y.; Sun, S. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology, 2010, 51(5), 1614-1623.
58. Shigoka, M.; Tsuchida, A.; Matsudo, T.; Nagakawa, Y.; Saito, H.; Suzuki, Y.; Aoki, T.; Murakami, Y.; Toyoda, H.; Kumada, T.; Bartenschlager, R.; Kato, N.; Ikeda, M.; Takashina, T.; Tanaka, M.; Suzuki, R.; Oikawa, K.; Takanashi, M.; Kuroda, M. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol. Int., 2010, 60(5), 351-357.
59. Yao, J.; Liang, L.; Huang, S.; Ding, J.; Tan, N.; Zhao, Y.; Yan, M.; Ge, C.; Zhang, Z.; Chen, T.; Wan, D.; Yao, M.; Li, J.; Gu, J.; He, X. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology, 2010, 51(3), 846-56.
60. Ding, J.; Huang, S.; Wu, S.; Zhao, Y.; Liang, L.; Yan, M.; Ge, C.; Yao, J.; Chen, T.; Wan, D.; Wang, H.; Gu, J.; Yao, M.; Li, J.; Tu, H.; He, X. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol., 2010, 12(4), 390-399.
61. Wang, B.; Hsu, S. H.; Majumder, S.; Kutay, H.; Huang, W.; Jacob, S. T.; Ghoshal, K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene, 2010, 29(12), 1787-1797.
62. Chen, Y.; Luo, J.; Tian, R.; Sun, H.; Zou, S. miR-373 Negatively Regulates Methyl-CpG-Binding Domain Protein 2 (MBD2) in Hilar Cholangiocarcinoma. Dig. Dis. Sci., 2010.
63. Veronese, A.; Lupini, L.; Consiglio, J.; Visone, R.; Ferracin, M.; Fornari, F.; Zanesi, N.; Alder, H.; D'Elia, G.; Gramantieri, L.; Bolondi, L.; Lanza, G.; Querzoli, P.; Angioni, A.; Croce, C. M.; Negrini, M. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res., 2010, 70(8), 3140-3149.
64. Lan, F. F.; Wang, H.; Chen, Y. C.; Chan, C. Y.; Ng, S. S.; Li, K.; Xie, D.; He, M. L.; Lin, M. C.; Kung, H. F. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c- Myc and upregulation of p16(INK4A), Int. J. Cancer, 2011, 128(2), 319-31.
65. Wong, C. C.; Wong, C. M.; Tung, E. K.; Au, S. L.; Lee, J. M.; Poon, R. T.; Man, K.; Ng, I. O. The MicroRNA miR-139 Suppresses Metastasis and Progression of Hepatocellular Carcinoma by Down-regulating Rho-Kinase 2. Gastroenterology, 2011, 140(1), 322-331.
66. Chen, Y.; Gao, W.; Luo, J.; Tian, R.; Sun, H.; Zou, S. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol. Rep., 2011, 25(2), 443-451.
67. Boige, V.; Laurent-Puig, P.; Fouchet, P.; Flejou, J. F.; Monges, G.; Bedossa, P.; Bioulac-Sage, P.; Capron, F.; Schmitz, A.; Olschwang, S.; Thomas, G. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a highresolution allelotype. Cancer Res, 1997, 57(10), 1986-1990.
68. Nagai, H.; Pineau, P.; Tiollais, P.; Buendia, M. A.; Dejean, A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene, 1997, 14(24), 2927-2933.
69. Lin, Y.; Shi, C. Y.; Li, B.; Soo, B. H.; Mohammed-Ali, S.; Wee, A.; Oon, C. J.; Mack, P. O.; Chan, S. H. Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Ann. Acad. Med. Singapore, 1996, 25(1), 22-30.
70. Higashitsuji, H.; Itoh, K.; Nagao, T.; Dawson, S.; Nonoguchi, K.; Kido, T.; Mayer, R. J.; Arii, S.; Fujita, J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med., 2000, 6(1), 96-99.
71. Scarola, M.; Schoeftner, S.; Schneider, C.; Benetti, R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53- dependent stress response. Cancer Res., 2010, 70(17), 6925-6933.
72. Tome, M.; Lopez-Romero, P.; Albo, C.; Sepulveda, J. C.; Fernandez-Gutierrez, B.; Dopazo, A.; Bernad, A.; Gonzalez, M. A. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ., 2010.
73. Fornari, F.; Gramantieri, L.; Ferracin, M.; Veronese, A.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Giovannini, C.; Croce, C. M.; Bolondi, L.; Negrini, M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27(43), 5651-5661.
74. Xu, X. R.; Huang, J.; Xu, Z. G.; Qian, B. Z.; Zhu, Z. D.; Yan, Q.; Cai, T.; Zhang, X.; Xiao, H. S.; Qu, J.; Liu, F.; Huang, Q. H.; Cheng, Z. H.; Li, N. G.; Du, J. J.; Hu, W.; Shen, K. T.; Lu, G.; Fu, G.; Zhong, M.; Xu, S. H.; Gu, W. Y.; Huang, W.; Zhao, X. T.; Hu, G. X.; Gu, J. R.; Chen, Z.; Han, Z. G. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl. Acad. Sci. USA, 2001, 98(26), 15089-15094.
75. Joo, M.; Kang, Y. K.; Kim, M. R.; Lee, H. K.; Jang, J. J. Cyclin D1 overexpression in hepatocellular carcinoma. Liver, 2001, 21(2), 89-95.
76. Hickman, E. S.; Moroni, M. C.; Helin, K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev, 2002, 12(1), 60-66.
77. Laurent-Puig, P.; Legoix, P.; Bluteau, O.; Belghiti, J.; Franco, D.; Binot, F.; Monges, G.; Thomas, G.; Bioulac-Sage, P.; Zucman-Rossi, J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 2001, 120(7), 1763-1773.
78. Weihrauch, M.; Benicke, M.; Lehnert, G.; Wittekind, C.; Wrbitzky, R.; Tannapfel, A. Frequent k- ras -2 mutations and p16(INK4A) methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br. J. Cancer, 2001, 84(7), 982-989.
79. Matsuda, Y.; Ichida, T.; Matsuzawa, J.; Sugimura, K.; Asakura, H. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology, 1999, 116(2), 394-400.
80. Xu, T.; Zhu, Y.; Xiong, Y.; Ge, Y. Y.; Yun, J. P.; Zhuang, S. M. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology, 2009, 50(1), 113-121.
81. Wu, M. H.; Ma, W. L.; Hsu, C. L.; Chen, Y. L.; Ou, J. H.; Ryan, C. K.; Hung, Y. C.; Yeh, S.; Chang, C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci. Transl. Med., 2010, 2(32), 32ra35.
82. Yeh, S. H.; Chen, P. J. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology, 2010, 78 Suppl 1,172-179.
83. Ito, Y.; Takeda, T.; Sakon, M.; Tsujimoto, M.; Monden, M.; Matsuura, N. Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology, 2001, 61(3), 221-225.
84. Medina, R.; Zaidi, S. K.; Liu, C. G.; Stein, J. L.; van Wijnen, A. J.; Croce, C. M.; Stein, G. S. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res., 2008, 68(8), 2773-2780.
85. le Sage, C.; Nagel, R.; Egan, D. A.; Schrier, M.; Mesman, E.; Mangiola, A.; Anile, C.; Maira, G.; Mercatelli, N.; Ciafre, S. A.; Farace, M. G.; Agami, R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. Embo. J., 2007, 26, 3699-3708.
86. Scelfo, R. A.; Schwienbacher, C.; Veronese, A.; Gramantieri, L.; Bolondi, L.; Querzoli, P.; Nenci, I.; Calin, G. A.; Angioni, A.; Barbanti-Brodano, G.; Negrini, M. Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene, 2002, 21(16), 2564-2572.
87. Schwienbacher, C.; Gramantieri, L.; Scelfo, R.; Veronese, A.; Calin, G. A.; Bolondi, L.; Croce, C. M.; Barbanti-Brodano, G.; Negrini, M. Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5445-5449.
88. Diaz-Meyer, N.; Day, C. D.; Khatod, K.; Maher, E. R.; Cooper, W.; Reik, W.; Junien, C.; Graham, G.; Algar, E.; Der Kaloustian, V. M.; Higgins, M. J. Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J. Med. Genet., 2003, 40(11), 797-801.
89. Soejima, H.; Nakagawachi, T.; Zhao, W.; Higashimoto, K.; Urano, T.; Matsukura, S.; Kitajima, Y.; Takeuchi, M.; Nakayama, M.; Oshimura, M.; Miyazaki, K.; Joh, K.; Mukai, T. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer. Oncogene, 2004, 23(25), 4380-4388.
90. Matsuda, Y.; Ichida, T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med. Mol. Morphol., 2006, 39(4), 169-175.
91. Petrocca, F.; Visone, R.; Onelli, M. R.; Shah, M. H.; Nicoloso, M. S.; de Martino, I.; Iliopoulos, D.; Pilozzi, E.; Liu, C. G.; Negrini, M.; Cavazzini, L.; Volinia, S.; Alder, H.; Ruco, L. P.; Baldassarre, G.; Croce, C. M.; Vecchione, A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell, 2008, 13(3), 272-286.
92. Carraro, G.; El-Hashash, A.; Guidolin, D.; Tiozzo, C.; Turcatel, G.; Young, B. M.; De Langhe, S. P.; Bellusci, S.; Shi, W.; Parnigotto, P. P.; Warburton, D. miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution. Dev. Biol., 2009, 333(2), 238-250.
93. Inomata, M.; Tagawa, H.; Guo, Y. M.; Kameoka, Y.; Takahashi, N.; Sawada, K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood, 2009, 113(2), 396-402.
94. O'Donnell, K. A.; Wentzel, E. A.; Zeller, K. I.; Dang, C. V.; Mendell, J. T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435(7043), 839-843.
95. Poliseno, L.; Pitto, L.; Simili, M.; Mariani, L.; Riccardi, L.; Ciucci, A.; Rizzo, M.; Evangelista, M.; Mercatanti, A.; Pandolfi, P. P.; Rainaldi, G. The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence. PLoS One, 2008, 3(7), e2542.
96. Sylvestre, Y.; De Guire, V.; Querido, E.; Mukhopadhyay, U. K.; Bourdeau, V.; Major, F.; Ferbeyre, G.; Chartrand, P. An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem., 2007, 282(4), 2135-2143.
97. Taguchi, A.; Yanagisawa, K.; Tanaka, M.; Cao, K.; Matsuyama, Y.; Goto, H.; Takahashi, T. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res., 2008, 68(14), 5540-5545.
98. Connolly, E.; Melegari, M.; Landgraf, P.; Tchaikovskaya, T.; Tennant, B. C.; Slagle, B. L.; Rogler, L. E.; Zavolan, M.; Tuschl, T.; Rogler, C. E. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol., 2008, 173(3), 856-864.
99. Fabregat, I.; Roncero, C.; Fernandez, M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int., 2007, 27(2), 155-162.
100. Guo, X. Z.; Shao, X. D.; Liu, M. P.; Xu, J. H.; Ren, L. N.; Zhao, J. J.; Li, H. Y.; Wang, D. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J. Gastroenterol., 2002, 8(6), 1059-1062.
101. Schattenberg, J. M.; Galle, P. R.; Schuchmann, M. Apoptosis in liver disease. Liver Int., 2006, 26(8), 904-911.
102. Charlotte, F.; L'Hermine, A.; Martin, N.; Geleyn, Y.; Nollet, M.; Gaulard, P.; Zafrani, E. S. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am. J. Pathol., 1994, 144(3), 460-465.
103. Takehara, T.; Liu, X.; Fujimoto, J.; Friedman, S. L.; Takahashi, H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology, 2001, 34(1), 55-61.
104. Garcia, E. J.; Lawson, D.; Cotsonis, G.; Cohen, C. Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl. Immunohistochem Mol. Morphol., 2002, 10(3), 210-217.
105. Watanabe, J.; Kushihata, F.; Honda, K.; Sugita, A.; Tateishi, N.; Mominoki, K.; Matsuda, S.; Kobayashi, N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery, 2004, 135(6), 604-612.
106. Beerheide, W.; Tan, Y. J.; Teng, E.; Ting, A. E.; Jedpiyawongse, A.; Srivatanakul, P. Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. Biochem. Biophys. Res. Commun., 2000, 273(1), 54-61.
107. Chen, G. G.; Lai, P. B.; Chan, P. K.; Chak, E. C.; Yip, J. H.; Ho, R. L.; Leung, B. C.; Lau, W. Y. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur. J. Cancer, 2001, 37(13), 1695-1702.
108. Yin, J.; Xiang, Q.; Yu, J.; Zhang, P. F.; Zu, X. Y.; Hu, N.; Zhu, B. Y.; Tang, S. S.; Liao, D. F.; Lei, X. Y. MiR-122 Increases Sensitivity of Drug-resistant BEL-7402/5-FU Cells to 5-Fluorouracil via Down-regulation of Bcl-2 Family Proteins, 2010.
109. Braconi, C.; Valeri, N.; Gasparini, P.; Huang, N.; Taccioli, C.; Nuovo, G.; Suzuki, T.; Croce, C. M.; Patel, T. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res., 2010, 16(3), 957-966.
110. Mott, J. L.; Kobayashi, S.; Bronk, S. F.; Gores, G. J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene, 2007, 26(42), 6133-6140.
111. Gramantieri, L.; Fornari, F.; Ferracin, M.; Veronese, A.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Croce, C. M.; Bolondi, L.; Negrini, M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res., 2009, 15(16), 5073-5081.
112. Schmelzle, T.; Mailleux, A. A.; Overholtzer, M.; Carroll, J. S.; Solimini, N. L.; Lightcap, E. S.; Veiby, O. P.; Brugge, J. S. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc. Natl. Acad. Sci. USA, 2007, 104(10), 3787-392.
113. Simpson, C. D.; Anyiwe, K.; Schimmer, A. D. Anoikis resistance and tumor metastasis. Cancer Lett., 2008, in press.
114. Padua, D.; Massague, J. Roles of TGFbeta in metastasis. Cell Res., 2009, 19(1), 89-102.
115. Yang, L. TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev., 2010, 29(2), 263-271.
116. Fu, H.; Tie, Y.; Xu, C.; Zhang, Z.; Zhu, J.; Shi, Y.; Jiang, H.; Sun, Z.; Zheng, X. Identification of human fetal liver miRNAs by a novel method. FEBS Lett., 2005, 579(17), 3849-3854.
117. Augello, C.; Caruso, L.; Maggioni, M.; Donadon, M.; Montorsi, M.; Santambrogio, R.; Torzilli, G.; Vaira, V.; Pellegrini, C.; Roncalli, M.; Coggi, G.; Bosari, S. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer, 2009, 9,125.
118. Saini, S.; Majid, S.; Yamamura, S.; Tabatabai, Z. L.; Suh, S. O.; Shahryari, V.; Chen, Y.; Deng, G.; Tanaka, Y.; Dahiya, R. Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res., 2010.
119. Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S. S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; Gasparini, P.; Gonelli, A.; Costinean, S.; Acunzo, M.; Condorelli, G.; Croce, C. M. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16(6), 498-509.
120. Roldo, C.; Missiaglia, E.; Hagan, J. P.; Falconi, M.; Capelli, P.; Bersani, S.; Calin, G. A.; Volinia, S.; Liu, C. G.; Scarpa, A.; Croce, C. M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol., 2006, 24(29), 4677-4684.
121. Schetter, A. J.; Leung, S. Y.; Sohn, J. J.; Zanetti, K. A.; Bowman, E. D.; Yanaihara, N.; Yuen, S. T.; Chan, T. L.; Kwong, D. L.; Au, G. K.; Liu, C. G.; Calin, G. A.; Croce, C. M.; Harris, C. C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 2008, 299(4), 425-436.
122. Yan, L. X.; Huang, X. F.; Shao, Q.; Huang, M. Y.; Deng, L.; Wu, Q. L.; Zeng, Y. X.; Shao, J. Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 2008, 14(11), 2348-2360.
123. Li, J.; Huang, H.; Sun, L.; Yang, M.; Pan, C.; Chen, W.; Wu, D.; Lin, Z.; Zeng, C.; Yao, Y.; Zhang, P.; Song, E. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res., 2009, 15(12), 3998-4008.
124. Gao, W.; Shen, H.; Liu, L.; Xu, J.; Shu, Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J. Cancer Res. Clin. Oncol., 2010.
125. Li, X.; Zhang, Y.; Ding, J.; Wu, K.; Fan, D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut, 2010, 59(5), 579-585.
126. Voortman, J.; Goto, A.; Mendiboure, J.; Sohn, J. J.; Schetter, A. J.; Saito, M.; Dunant, A.; Pham, T. C.; Petrini, I.; Lee, A.; Khan, M. A.; Hainaut, P.; Pignon, J. P.; Brambilla, E.; Popper, H. H.; Filipits, M.; Harris, C. C.; Giaccone, G. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res., 2010, 70(21), 8288-8298.
127. Zhi, F.; Chen, X.; Wang, S.; Xia, X.; Shi, Y.; Guan, W.; Shao, N.; Qu, H.; Yang, C.; Zhang, Y.; Wang, Q.; Wang, R.; Zen, K.; Zhang, C. Y.; Zhang, J.; Yang, Y. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur. J. Cancer, 2010, 46(9), 1640-1649.
128. Hu, Y.; Correa, A. M.; Hoque, A.; Guan, B.; Ye, F.; Huang, J.; Swisher, S. G.; Wu, T. T.; Ajani, J. A.; Xu, X. C. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int. J. Cancer, 2011, 128(1), 132-143.
129. Meng, F.; Henson, R.; Lang, M.; Wehbe, H.; Maheshwari, S.; Mendell, J. T.; Jiang, J.; Schmittgen, T. D.; Patel, T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 2006, 130(7), 2113-2129.
130. Blower, P. E.; Chung, J. H.; Verducci, J. S.; Lin, S.; Park, J. K.; Dai, Z.; Liu, C. G.; Schmittgen, T. D.; Reinhold, W. C.; Croce, C. M.; Weinstein, J. N.; Sadee, W. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther., 2008, 7(1), 1-9.
131. Shi, L.; Chen, J.; Yang, J.; Pan, T.; Zhang, S.; Wang, Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res., 2010, 1352, 255-264.
132. Tomimaru, Y.; Eguchi, H.; Nagano, H.; Wada, H.; Tomokuni, A.; Kobayashi, S.; Marubashi, S.; Takeda, Y.; Tanemura, M.; Umeshita, K.; Doki, Y.; Mori, M. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br. J. Cancer, 2010, 103(10), 1617-1626.
133. Sayed, D.; He, M.; Hong, C.; Gao, S.; Rane, S.; Yang, Z.; Abdellatif, M. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J. Biol. Chem., 2010, 285(26), 20281-20290.
134. Zhang, J. G.; Wang, J. J.; Zhao, F.; Liu, Q.; Jiang, K.; Yang, G. H. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC), Clin. Chim. Acta, 2010, 411(11-12), 846-852.
135. Asangani, I. A.; Rasheed, S. A.; Nikolova, D. A.; Leupold, J. H.; Colburn, N. H.; Post, S.; Allgayer, H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene, 2008, 27(15), 2128-2136.
136. Chen, Y.; Liu, W.; Chao, T.; Zhang, Y.; Yan, X.; Gong, Y.; Qiang, B.; Yuan, J.; Sun, M.; Peng, X. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett., 2008, 272(2), 197-205.
137. Frankel, L. B.; Christoffersen, N. R.; Jacobsen, A.; Lindow, M.; Krogh, A.; Lund, A. H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem., 2008, 283(2), 1026-1033.
138. Lu, Z.; Liu, M.; Stribinskis, V.; Klinge, C. M.; Ramos, K. S.; Colburn, N. H.; Li, Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 2008, 27(31), 4373-4379.
139. Motoyama, K.; Inoue, H.; Mimori, K.; Tanaka, F.; Kojima, K.; Uetake, H.; Sugihara, K.; Mori, M. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int. J. Oncol., 2010, 36(5), 1089-1095.
140. Selaru, F. M.; Olaru, A. V.; Kan, T.; David, S.; Cheng, Y.; Mori, Y.; Yang, J.; Paun, B.; Jin, Z.; Agarwal, R.; Hamilton, J. P.; Abraham, J.; Georgiades, C.; Alvarez, H.; Vivekanandan, P.; Yu, W.; Maitra, A.; Torbenson, M.; Thuluvath, P. J.; Gores, G. J.; LaRusso, N. F.; Hruban, R.; Meltzer, S. J. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, 2009, 49(5), 1595-6101.
141. Yao, Q.; Xu, H.; Zhang, Q. Q.; Zhou, H.; Qu, L. H. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun., 2009, 388(3), 539-542.
142. Bressac, B.; Kew, M.; Wands, J.; Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 1991, 350(6317), 429-341.
143. Lu, W.; Lo, S. Y.; Chen, M.; Wu, K.; Fung, Y. K.; Ou, J. H. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology, 1999, 264(1), 134-141.
144. Spizzo, R.; Nicoloso, M. S.; Lupini, L.; Lu, Y.; Fogarty, J.; Rossi, S.; Zagatti, B.; Fabbri, M.; Veronese, A.; Liu, X.; Davuluri, R.; Croce, C. M.; Mills, G.; Negrini, M.; Calin, G. A. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ., 2010, 17(2), 246-254.
145. Pineau, P.; Volinia, S.; McJunkin, K.; Marchio, A.; Battiston, C.; Terris, B.; Mazzaferro, V.; Lowe, S. W.; Croce, C. M.; Dejean, A. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sc USA, 2010, 107(1), 264-269.
146. Chang, T. C.; Wentzel, E. A.; Kent, O. A.; Ramachandran, K.; Mullendore, M.; Lee, K. H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C. J.; Arking, D. E.; Beer, M. A.; Maitra, A.; Mendell, J. T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 2007, 26(5), 745-752.
147. He, L.; He, X.; Lim, L. P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; Jackson, A. L.; Linsley, P. S.; Chen, C.; Lowe, S. W.; Cleary, M. A.; Hannon, G. J. A microRNA component of the p53 tumour suppressor network. Nature, 2007, 447(7148), 1130-1134.
148. He, X.; He, L.; Hannon, G. J. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res., 2007, 67(23), 11099-11101.
149. Hermeking, H. p53 enters the microRNA world. Cancer Cell, 2007, 12(5), 414-418.
150. Raver-Shapira, N.; Marciano, E.; Meiri, E.; Spector, Y.; Rosenfeld, N.; Moskovits, N.; Bentwich, Z.; Oren, M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell, 2007, 26(5), 731-743.
151. Tarasov, V.; Jung, P.; Verdoodt, B.; Lodygin, D.; Epanchintsev, A.; Menssen, A.; Meister, G.; Hermeking, H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 2007, 6(13), 1586-1593.
152. Sachdeva, M.; Zhu, S.; Wu, F.; Wu, H.; Walia, V.; Kumar, S.; Elble, R.; Watabe, K.; Mo, Y. Y. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA, 2009, 106(9), 3207-3212.
153. Georges, S. A.; Biery, M. C.; Kim, S. Y.; Schelter, J. M.; Guo, J.; Chang, A. N.; Jackson, A. L.; Carleton, M. O.; Linsley, P. S.; Cleary, M. A.; Chau, B. N. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res., 2008, 68(24), 10105-10112.
154. Braun, C. J.; Zhang, X.; Savelyeva, I.; Wolff, S.; Moll, U. M.; Schepeler, T.; Orntoft, T. F.; Andersen, C. L.; Dobbelstein, M. p53- Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res., 2008, 68(24), 10094-10104.
155. Ito, Y.; Sasaki, Y.; Horimoto, M.; Wada, S.; Tanaka, Y.; Kasahara, A.; Ueki, T.; Hirano, T.; Yamamoto, H.; Fujimoto, J.; Okamoto, E.; Hayashi, N.; Hori, M. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology, 1998, 27(4), 951-958.
156. Motoo, Y.; Sawabu, N.; Yamaguchi, Y.; Terada, T.; Nakanuma, Y. Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor. Oncology, 1993, 50(4), 270-274.
157. Rosmorduc, O.; Wendum, D.; Corpechot, C.; Galy, B.; Sebbagh, N.; Raleigh, J.; Housset, C.; Poupon, R. Hepatocellular hypoxiainduced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am. J. Pathol, 1999, 155(4), 1065-73.
158. Uematsu, S.; Higashi, T.; Nouso, K.; Kariyama, K.; Nakamura, S.; Suzuki, M.; Nakatsukasa, H.; Kobayashi, Y.; Hanafusa, T.; Tsuji, T.; Shiratori, Y. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2005, 20(4), 583-588.
159. Sugano, Y.; Matsuzaki, K.; Tahashi, Y.; Furukawa, F.; Mori, S.; Yamagata, H.; Yoshida, K.; Matsushita, M.; Nishizawa, M.; Fujisawa, J.; Inoue, K. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene, 2003, 22(15), 2309-
160. Moon, W. S.; Rhyu, K. H.; Kang, M. J.; Lee, D. G.; Yu, H. C.; Yeum, J. H.; Koh, G. Y.; Tarnawski, A. S. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod. Pathol., 2003, 16(6), 552-557.
161. Hirohashi, K.; Yamamoto, T.; Uenishi, T.; Ogawa, M.; Sakabe, K.; Takemura, S.; Shuto, T.; Tanaka, H.; Kubo, S.; Kinoshita, H. CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepatogastroenterology, 2004, 51(58), 1121-1123.
162. Ferrero, S.; Ragni, N. Prognostic value of plasma and serum VEGF levels in patients with resectable hepatocellular carcinoma. Ann. Surg. Oncol., 2003, 10(9), 1123.
163. Iguchi, H.; Yokota, M.; Fukutomi, M.; Uchimura, K.; Yonemasu, H.; Hachitanda, Y.; Nakao, Y.; Tanaka, Y.; Sumii, T.; Funakoshi, A. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res., 2002, 21(3), 309-313.
164. Schmitt, M.; Horbach, A.; Kubitz, R.; Frilling, A.; Haussinger, D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J. Hepatol., 2004, 41(2), 274-283.
165. Dhar, D. K.; Naora, H.; Yamanoi, A.; Ono, T.; Kohno, H.; Otani, H.; Nagasue, N. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res., 2002, 22(1A), 379-386.
166. Liu, B.; Peng, X. C.; Zheng, X. L.; Wang, J.; Qin, Y. W. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer, 2009, 66(2), 169-175.
167. Cascio, S.; D'Andrea, A.; Ferla, R.; Surmacz, E.; Gulotta, E.; Amodeo, V.; Bazan, V.; Gebbia, N.; Russo, A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J. Cell Physiol., 2010, 224(1), 242-249.
168. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 2003, 4(12), 915-925.
169. Benvenuti, S.; Comoglio, P. M. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell Physiol., 2007, 213(2), 316-325.
170. Stuart, K. A.; Riordan, S. M.; Lidder, S.; Crostella, L.; Williams, R.; Skouteris, G. G. Hepatocyte growth factor/scatter factorinduced intracellular signalling. Int. J. Exp. Pathol., 2000, 81(1), 17-30.
171. Lee, K. H.; Choi, E. Y.; Hyun, M. S.; Jang, B. I.; Kim, T. N.; Lee, H. J.; Eun, J. Y.; Kim, H. G.; Yoon, S. S.; Lee, D. S.; Kim, J. H.; Kim, J. R. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin. Exp. Metastasis, 2008, 25(1), 89-96.
172. Boix, L.; Rosa, J. L.; Ventura, F.; Castells, A.; Bruix, J.; Rodes, J.; Bartrons, R. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology, 1994, 19(1), 88-91.
173. Suzuki, K.; Hayashi, N.; Yamada, Y.; Yoshihara, H.; Miyamoto, Y.; Ito, Y.; Ito, T.; Katayama, K.; Sasaki, Y.; Ito, A.; et al. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology, 1994, 20(5), 1231-1236.
174. Grigioni, W. F.; Fiorentino, M.; D'Errico, A.; Ponzetto, A.; Crepaldi, T.; Prat, M.; Comoglio, P. M. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology, 1995, 21(6), 1543-1546.
175. Ueki, T.; Fujimoto, J.; Suzuki, T.; Yamamoto, H.; Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology, 1997, 25(3), 619-623.
176. Kim, S.; Lee, U. J.; Kim, M. N.; Lee, E. J.; Kim, J. Y.; Lee, M. Y.; Choung, S.; Kim, Y. J.; Choi, Y. C. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2), J. Biol. Chem., 2008, 283(26), 18158-18166.
177. Jagirdar, J.; Nonomura, A.; Patil, J.; Thor, A.; Paronetto, F. ras oncogene p21 expression in hepatocellular carcinoma. J. Exp. Pathol., 1989, 4(1), 37-46.
178. Takada, S.; Koike, K. Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. Oncogene, 1989, 4(2), 189-193.
179. Challen, C.; Guo, K.; Collier, J. D.; Cavanagh, D.; Bassendine, M. F. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J. Hepatol., 1992, 14(2-3), 342-346.
180. Akao, Y.; Nakagawa, Y.; Naoe, T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull., 2006, 29(5), 903-906.
181. Bussing, I.; Slack, F. J.; Grosshans, H. let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med., 2008, 14, 400-409.
182. Johnson, S. M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K. L.; Brown, D.; Slack, F. J. RAS is regulated by the let-7 microRNA family. Cell, 2005, 120(5), 635-647.
183. Lee, Y. S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev., 2007, 21(9), 1025-1030.
184. Mayr, C.; Hemann, M. T.; Bartel, D. P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 2007, 315(5818), 1576-1579.
185. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y.; Mitsudomi, T.; Takahashi, T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res., 2004, 64(11), 3753-3756.
186. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 2007, 131(6), 1109-1123.
187. Liu, C.; Yu, J.; Yu, S.; Lavker, R. M.; Cai, L.; Liu, W.; Yang, K.; He, X.; Chen, S. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J. Hepatol., 2010, 53(1), 98-107.
188. Villanueva, A.; Chiang, D. Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguez, B.; Sole, M.; Battiston, C.; Van Laarhoven, S.; Fiel, M. I.; Di Feo, A.; Hoshida, Y.; Yea, S.; Toffanin, S.; Ramos, A.; Martignetti, J. A.; Mazzaferro, V.; Bruix, J.; Waxman, S.; Schwartz, M.; Meyerson, M.; Friedman, S. L.; Llovet, J. M. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology, 2008, 135(6), 1972-1983, 83 e1-11.
189. Zhou, L.; Huang, Y.; Li, J.; Wang, Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med. Oncol., 2010, 27(2), 255-2561.
190. Ichimi, T.; Enokida, H.; Okuno, Y.; Kunimoto, R.; Chiyomaru, T.; Kawamoto, K.; Kawahara, K.; Toki, K.; Kawakami, K.; Nishiyama, K.; Tsujimoto, G.; Nakagawa, M.; Seki, N. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer, 2009, 125(2), 345-352.
191. Iorio, M. V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C. G.; Alder, H.; Calin, G. A.; Menard, S.; Croce, C. M. MicroRNA signatures in human ovarian cancer. Cancer Res., 2007, 67(18), 8699-8707.
192. Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A. O.; Landthaler, M.; Lin, C.; Socci, N. D.; Hermida, L.; Fulci, V.; Chiaretti, S.; Foa, R.; Schliwka, J.; Fuchs, U.; Novosel, A.; Muller, R. U.; Schermer, B.; Bissels, U.; Inman, J.; Phan, Q.; Chien, M.; Weir, D. B.; Choksi, R.; De Vita, G.; Frezzetti, D.; Trompeter, H. I.; Hornung, V.; Teng, G.; Hartmann, G.; Palkovits, M.; Di Lauro, R.; Wernet, P.; Macino, G.; Rogler, C. E.; Nagle, J. W.; Ju, J.; Papavasiliou, F. N.; Benzing, T.; Lichter, P.; Tam, W.; Brownstein, M. J.; Bosio, A.; Borkhardt, A.; Russo, J. J.; Sander, C.; Zavolan, M.; Tuschl, T. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 2007, 129(7), 1401-1414.
193. Dolganiuc, A.; Petrasek, J.; Kodys, K.; Catalano, D.; Mandrekar, P.; Velayudham, A.; Szabo, G. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin. Exp. Res., 2009, 33(10), 1704-1710.
194. Connolly, E. C.; Van Doorslaer, K.; Rogler, L. E.; Rogler, C. E. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol. Cancer Res., 2010, 8(5), 691-700.
195. Gabriely, G.; Wurdinger, T.; Kesari, S.; Esau, C. C.; Burchard, J.; Linsley, P. S.; Krichevsky, A. M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell Biol., 2008, 28(17), 5369-5380.
196. Song, B.; Wang, C.; Liu, J.; Wang, X.; Lv, L.; Wei, L.; Xie, L.; Zheng, Y.; Song, X. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J. Exp. Clin. Cancer Res., 2010, 29, 29.
197. Zhu, S.; Wu, H.; Wu, F.; Nie, D.; Sheng, S.; Mo, Y. Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res., 2008, 18(3), 350-359.
198. Polakis, P. Wnt signaling and cancer. Genes Dev., 2000, 14(15), 1837-1851.
199. Fodde, R.; Brabletz, T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin.Cell Biol., 2007, 19(2), 150-158.
200. Vermeulen, L.; De Sousa, E. M. F.; van der Heijden, M.; Cameron, K.; de Jong, J. H.; Borovski, T.; Tuynman, J. B.; Todaro, M.; Merz, C.; Rodermond, H.; Sprick, M. R.; Kemper, K.; Richel, D. J.; Stassi, G.; Medema, J. P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol., 2010, 12(5), 468-476.
201. Wend, P.; Holland, J. D.; Ziebold, U.; Birchmeier, W. Wnt signaling in stem and cancer stem cells. Semin. Cell Dev. Biol., 2010, 21(8), 855-863.
202. Thompson, M. D.; Monga, S. P. WNT/beta-catenin signaling in liver health and disease. Hepatology, 2007, 45(5), 1298-1305.
203. Micsenyi, A.; Tan, X.; Sneddon, T.; Luo, J. H.; Michalopoulos, G. K.; Monga, S. P. Beta-catenin is temporally regulated during normal liver development. Gastroenterology, 2004, 126(4), 1134-1146.
204. Monga, S. P.; Monga, H. K.; Tan, X.; Mule, K.; Pediaditakis, P.; Michalopoulos, G. K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology, 2003, 124(1), 202-216.
205. Monga, S. P.; Pediaditakis, P.; Mule, K.; Stolz, D. B.; Michalopoulos, G. K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology, 2001, 33(5), 1098-1109.
206. Hu, M.; Kurobe, M.; Jeong, Y. J.; Fuerer, C.; Ghole, S.; Nusse, R.; Sylvester, K. G. Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitor cells. Gastroenterology, 2007, 133(5), 1579-1591.
207. Apte, U.; Thompson, M. D.; Cui, S.; Liu, B.; Cieply, B.; Monga, S. P. Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology, 2008, 47(1), 288-295.
208. Satoh, S.; Daigo, Y.; Furukawa, Y.; Kato, T.; Miwa, N.; Nishiwaki, T.; Kawasoe, T.; Ishiguro, H.; Fujita, M.; Tokino, T.; Sasaki, Y.; Imaoka, S.; Murata, M.; Shimano, T.; Yamaoka, Y.; Nakamura, Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet., 2000, 24(3), 245-250.
209. Ding, Q.; Xia, W.; Liu, J. C.; Yang, J. Y.; Lee, D. F.; Xia, J.; Bartholomeusz, G.; Li, Y.; Pan, Y.; Li, Z.; Bargou, R. C.; Qin, J.; Lai, C. C.; Tsai, F. J.; Tsai, C. H.; Hung, M. C. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell, 2005, 19(2), 159-170.
210. Zucman-Rossi, J.; Jeannot, E.; Nhieu, J. T.; Scoazec, J. Y.; Guettier, C.; Rebouissou, S.; Bacq, Y.; Leteurtre, E.; Paradis, V.; Michalak, S.; Wendum, D.; Chiche, L.; Fabre, M.; Mellottee, L.; Laurent, C.; Partensky, C.; Castaing, D.; Zafrani, E. S.; Laurent-Puig, P.; Balabaud, C.; Bioulac-Sage, P. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology, 2006, 43(3), 515-524.
211. Brabletz, T.; Hlubek, F.; Spaderna, S.; Schmalhofer, O.; Hiendlmeyer, E.; Jung, A.; Kirchner, T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal- epithelial transition, stem cells and beta-catenin. Cells Tissues Organs, 2005, 179(1-2), 56-65.
212. Liu, L.; Zhu, X. D.; Wang, W. Q.; Shen, Y.; Qin, Y.; Ren, Z. G.; Sun, H. C.; Tang, Z. Y. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin. Cancer Res., 2010, 16(10), 2740-2750.
213. Neth, P.; Ries, C.; Karow, M.; Egea, V.; Ilmer, M.; Jochum, M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev., 2007, 3(1), 18-29.
214. Nguyen, D. X.; Chiang, A. C.; Zhang, X. H.; Kim, J. Y.; Kris, M. G.; Ladanyi, M.; Gerald, W. L.; Massague, J. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell, 2009, 138(1), 51-62.
215. Huang, K.; Zhang, J. X.; Han, L.; You, Y. P.; Jiang, T.; Pu, P. Y.; Kang, C. S. MicroRNA roles in beta-catenin pathway. Mol. Cancer, 2010, 9, 252.
216. Silver, S. J.; Hagen, J. W.; Okamura, K.; Perrimon, N.; Lai, E. C. Functional screening identifies miR-315 as a potent activator of Wingless signaling. Proc. Natl. Acad. Sci. USA, 2007, 104(46), 18151-18156.
217. Saydam, O.; Shen, Y.; Wurdinger, T.; Senol, O.; Boke, E.; James, M. F.; Tannous, B. A.; Stemmer-Rachamimov, A. O.; Yi, M.; Stephens, R. M.; Fraefel, C.; Gusella, J. F.; Krichevsky, A. M.; Breakefield, X. O. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol. Cell Biol., 2009, 29(21), 5923-5940.
218. De Wever, O.; Pauwels, P.; De Craene, B.; Sabbah, M.; Emami, S.; Redeuilh, G.; Gespach, C.; Bracke, M.; Berx, G. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem. Cell Biol., 2008, 130(3), 481-494.
219. Kennell, J. A.; Gerin, I.; MacDougald, O. A.; Cadigan, K. M. The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc. Natl. Acad. Sci. USA, 2008, 105(40), 15417-15422.
220. Hashimi, S. T.; Fulcher, J. A.; Chang, M. H.; Gov, L.; Wang, S.; Lee, B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood, 2009, 114(2), 404-414.
221. Li, H.; Bian, C.; Liao, L.; Li, J.; Zhao, R. C. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res. Treat, 2010.
222. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol., 2002, 12(9), 735-739.
223. Chang, J.; Nicolas, E.; Marks, D.; Sander, C.; Lerro, A.; Buendia, M. A.; Xu, C.; Mason, W. S.; Moloshok, T.; Bort, R.; Zaret, K. S.; Taylor, J. M. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol., 2004, 1(2), 106-113.
224. Xu, H.; He, J. H.; Xiao, Z. D.; Zhang, Q. Q.; Chen, Y. Q.; Zhou, H.; Qu, L. H. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology, 2010, 52(4), 1431-1442.
225. Esau, C.; Davis, S.; Murray, S. F.; Yu, X. X.; Pandey, S. K.; Pear, M.; Watts, L.; Booten, S. L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B. A.; Freier, S.; Bennett, C. F.; Bhanot, S.; Monia, B. P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 2006, 3(2), 87-98.
226. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438(7068), 685-689.
227. Krutzfeldt, J.; Stoffel, M. MicroRNAs: a new class of regulatory genes affecting metabolism. Cell Metab., 2006, 4(1), 9-12.
228. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H. F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E. M.; Kauppinen, S. LNA-mediated microRNA silencing in non-human primates. Nature, 2008, 452(7189), 896-899.
229. Wu, X.; Wu, S.; Tong, L.; Luan, T.; Lin, L.; Lu, S.; Zhao, W.; Ma, Q.; Liu, H.; Zhong, Z. miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Scand. J. Gastroenterol., 2009, 44(11), 1332-1339.
230. Diao, S.; Zhang, J. F.; Wang, H.; He, M. L.; Lin, M. C.; Chen, Y.; Kung, H. F. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. Proteomics, 2010, 10(20), 3723-3731.
231. Zauberman, A.; Lupo, A.; Oren, M. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene, 1995, 10(12), 2361-2366.
232. Okamoto, K.; Beach, D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. Embo J, 1994, 13(20), 4816-22.
233. Endo, Y.; Fujita, T.; Tamura, K.; Tsuruga, H.; Nojima, H. Structure and chromosomal assignment of the human cyclin G gene. Genomics, 1996, 38(1), 92-95.
234. Jensen, M. R.; Factor, V. M.; Zimonjic, D. B.; Miller, M. J.; Keck, C. L.; Thorgeirsson, S. S. Chromosome localization and structure of the murine cyclin G1 gene promoter sequence. Genomics, 1997, 45(2), 297-303.
235. Okamoto, K.; Li, H.; Jensen, M. R.; Zhang, T.; Taya, Y.; Thorgeirsson, S. S.; Prives, C. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol. Cell, 2002, 9(4), 761-771.
236. Ohtsuka, T.; Jensen, M. R.; Kim, H. G.; Kim, K. T.; Lee, S. W. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene, 2004, 23(31), 5405-5408.
237. Kampmeier, J.; Behrens, A.; Wang, Y.; Yee, A.; Anderson, W. F.; Hall, F. L.; Gordon, E. M.; McDonnell, P. J. Inhibition of rabbit keratocyte and human fetal lens epithelial cell proliferation by retrovirus- mediated transfer of antisense cyclin G1 and antisense MAT1 constructs. Hum. Gene Ther., 2000, 11(1), 1-8.
238. Gordon, E. M.; Liu, P. X.; Chen, Z. H.; Liu, L.; Whitley, M. D.; Gee, C.; Groshen, S.; Hinton, D. R.; Beart, R. W.; Hall, F. L. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res., 2000, 60(13), 3343-3347.
239. Skotzko, M.; Wu, L.; Anderson, W. F.; Gordon, E. M.; Hall, F. L. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res, 1995, 55(23), 5493-5498.
240. Jensen, M. R.; Factor, V. M.; Fantozzi, A.; Helin, K.; Huh, C. G.; Thorgeirsson, S. S. Reduced hepatic tumor incidence in cyclin G1- deficient mice. Hepatology, 2003, 37(4), 862-870.
241. Henke, J. I.; Goergen, D.; Zheng, J.; Song, Y.; Schuttler, C. G.; Fehr, C.; Junemann, C.; Niepmann, M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J., 2008, 27(24), 3300-3310.
242. Chang, J.; Guo, J. T.; Jiang, D.; Guo, H.; Taylor, J. M.; Block, T. M. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J. Virol., 2008, 82(16), 8215-23.
243. Jopling, C. L.; Yi, M.; Lancaster, A. M.; Lemon, S. M.; Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005, 309(5740), 1577-81.
244. Murakami, Y.; Aly, H. H.; Tajima, A.; Inoue, I.; Shimotohno, K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol., 2009, 50(3), 453-460.
245. Lee, Y. B.; Bantounas, I.; Lee, D. Y.; Phylactou, L.; Caldwell, M. A.; Uney, J. B. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res., 2009, 37(1), 123-128.
246. Ura, S.; Honda, M.; Yamashita, T.; Ueda, T.; Takatori, H.; Nishino, R.; Sunakozaka, H.; Sakai, Y.; Horimoto, K.; Kaneko, S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology, 2009, 49(4), 1098-1112.
247. Huang, X. H.; Wang, Q.; Chen, J. S.; Fu, X. H.; Chen, X. L.; Chen, L. Z.; Li, W.; Bi, J.; Zhang, L. J.; Fu, Q.; Zeng, W. T.; Cao, L. Q.; Tan, H. X.; Su, Q. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res., 2009, 39(8), 786-794.
248. Huang, Y. S.; Dai, Y.; Yu, X. F.; Bao, S. Y.; Yin, Y. B.; Tang, M.; Hu, C. X. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J. Gastroenterol. Hepatol., 2008, 23(1), 87-94.
249. Rane, S.; He, M.; Sayed, D.; Vashistha, H.; Malhotra, A.; Sadoshima, J.; Vatner, D. E.; Vatner, S. F.; Abdellatif, M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ. Res., 2009, 104(7), 879-886.
250. Loscalzo, J. The cellular response to hypoxia: tuning the system with microRNAs. J. Clin. Invest., 2010, 120(11), 3815-3817.
251. Huang, G. W.; Yang, L. Y.; Lu, W. Q. Expression of hypoxiainducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J. Gastroenterol., 2005, 11(11), 1705-1708.
252. Lin, E. A.; Kong, L.; Bai, X. H.; Luan, Y.; Liu, C. J. miR-199a, a bone morphogenic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1. J. Biol. Chem., 2009, 284(17), 11326-11335.
253. Oskowitz, A. Z.; Lu, J.; Penfornis, P.; Ylostalo, J.; McBride, J.; Flemington, E. K.; Prockop, D. J.; Pochampally, R. Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc. Natl. Acad. Sci. USA, 2008, 105(47), 18372-18377.
254. Schulte, J. H.; Horn, S.; Otto, T.; Samans, B.; Heukamp, L. C.; Eilers, U. C.; Krause, M.; Astrahantseff, K.; Klein-Hitpass, L.; Buettner, R.; Schramm, A.; Christiansen, H.; Eilers, M.; Eggert, A.; Berwanger, B. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int. J. Cancer, 2008, 122(3), 699-704.
255. Ciafre, S. A.; Galardi, S.; Mangiola, A.; Ferracin, M.; Liu, C. G.; Sabatino, G.; Negrini, M.; Maira, G.; Croce, C. M.; Farace, M. G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun., 2005, 334(4), 1351-1358.
256. He, H.; Jazdzewski, K.; Li, W.; Liyanarachchi, S.; Nagy, R.; Volinia, S.; Calin, G. A.; Liu, C. G.; Franssila, K.; Suster, S.; Kloos, R. T.; Croce, C. M.; de la Chapelle, A. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA, 2005, 102(52), 19075-19080.
257. Lee, E. J.; Gusev, Y.; Jiang, J.; Nuovo, G. J.; Lerner, M. R.; Frankel, W. L.; Morgan, D. L.; Postier, R. G.; Brackett, D. J.; Schmittgen, T. D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer, 2006.
258. Pallante, P.; Visone, R.; Ferracin, M.; Ferraro, A.; Berlingieri, M. T.; Troncone, G.; Chiappetta, G.; Liu, C. G.; Santoro, M.; Negrini, M.; Croce, C. M.; Fusco, A. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer, 2006, 13(2), 497-508.
259. Galardi, S.; Mercatelli, N.; Giorda, E.; Massalini, S.; Frajese, G. V.; Ciafre, S. A.; Farace, M. G. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J. Biol. Chem., 2007, 282(32), 23716-23724.
260. Gottardo, F.; Liu, C. G.; Ferracin, M.; Calin, G. A.; Fassan, M.; Bassi, P.; Sevignani, C.; Byrne, D.; Negrini, M.; Pagano, F.; Gomella, L. G.; Croce, C. M.; Baffa, R. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol, 2007, 25(5), 387-392.
261. Chun-Zhi, Z.; Lei, H.; An-Ling, Z.; Yan-Chao, F.; Xiao, Y.; Guang-Xiu, W.; Zhi-Fan, J.; Pei-Yu, P.; Qing-Yu, Z.; Chun-Sheng, K. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer, 2010, 10, 367.
262. DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev., 2008, 22(2), 239-251.
263. Krichevsky, A. M.; Gabriely, G. miR-21: a small multi-faceted RNA. J. Cell Mol. Med., 2009, 13(1), 39-53.
264. Marquez, R. T.; Wendlandt, E.; Galle, C. S.; Keck, K.; McCaffrey, A. P. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298(4), G535-G541.
265. Vinciguerra, M.; Carrozzino, F.; Peyrou, M.; Carlone, S.; Montesano, R.; Benelli, R.; Foti, M. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J. Hepatol., 2009, 50(6), 1132-1141.
266. Iimuro, Y.; Fujimoto, J. TLRs, NF-kappaB, JNK, and Liver Regeneration. Gastroenterol. Res. Pract., 2010, 2010.
267. Song, G.; Sharma, A. D.; Roll, G. R.; Ng, R.; Lee, A. Y.; Blelloch, R. H.; Frandsen, N. M.; Willenbring, H. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology, 2010, 51(5), 1735-1743.
268. Chan, J. A.; Krichevsky, A. M.; Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res., 2005, 65(14), 6029-6033.
269. Iorio, M. V.; Ferracin, M.; Liu, C. G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J. P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G. A.; Querzoli, P.; Negrini, M.; Croce, C. M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005, 65(16), 7065-7070.
270. Li, T.; Li, D.; Sha, J.; Sun, P.; Huang, Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun., 2009, 383(3), 280-285.
271. Si, M. L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y. Y. miR-21- mediated tumor growth. Oncogene, 2007, 26(19), 2799-2803.
272. Medina, P. P.; Nolde, M.; Slack, F. J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010.
273. Li, Y.; Li, W.; Yang, Y.; Lu, Y.; He, C.; Hu, G.; Liu, H.; Chen, J.; He, J.; Yu, H. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res., 2009, 1286,13-18.
274. Zhu, S.; Si, M. L.; Wu, H.; Mo, Y. Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1), J Biol Chem, 2007, 282(19), 14328-36.
275. Bruix, J.; Sherman, M.; Llovet, J. M.; Beaugrand, M.; Lencioni, R.; Burroughs, A. K.; Christensen, E.; Pagliaro, L.; Colombo, M.; Rodes, J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol., 2001, 35(3), 421-430.
276. Okuda, K.; Ohtsuki, T.; Obata, H.; Tomimatsu, M.; Okazaki, N.; Hasegawa, H.; Nakajima, Y.; Ohnishi, K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 1985, 56(4), 918-928.
277. Japan, L. C. S. G. o. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer, 1994, 74(10), 2772-2780.
278. Chevret, S.; Trinchet, J. C.; Mathieu, D.; Rached, A. A.; Beaugrand, M.; Chastang, C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol., 1999, 31(1), 133-141.
279. (CLIP), T. C. o. t. L. I. P. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology, 2000, 31(4), 840-845.
280. Leung, T. W.; Tang, A. M.; Zee, B.; Lau, W. Y.; Lai, P. B.; Leung, K. L.; Lau, J. T.; Yu, S. C.; Johnson, P. J. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer, 2002, 94(6), 1760-1769.
281. Barbara, L.; Benzi, G.; Gaiani, S.; Fusconi, F.; Zironi, G.; Siringo, S.; Rigamonti, A.; Barbara, C.; Grigioni, W.; Mazziotti, A.; et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology, 1992, 16(1), 132-137.
282. Bruix, J.; Boix, L.; Sala, M.; Llovet, J. M. Focus on hepatocellular carcinoma. Cancer Cell, 2004, 5(3), 215-219.
283. Villanueva, A.; Hoshida, Y.; Toffanin, S.; Lachenmayer, A.; Alsinet, C.; Savic, R.; Cornella, H.; Llovet, J. M. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin. Cancer Res., 2010, 16(19), 4688-4694.
284. Kaposi-Novak, P.; Lee, J. S.; Gomez-Quiroz, L.; Coulouarn, C.; Factor, V. M.; Thorgeirsson, S. S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest., 2006, 116(6), 1582-1595.
285. Ito, Y.; Matsuura, N.; Sakon, M.; Miyoshi, E.; Noda, K.; Takeda, T.; Umeshita, K.; Nagano, H.; Nakamori, S.; Dono, K.; Tsujimoto, M.; Nakahara, M.; Nakao, K.; Taniguchi, N.; Monden, M. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology, 1999, 30(1), 90-99.
286. Tannapfel, A.; Grund, D.; Katalinic, A.; Uhlmann, D.; Kockerling, F.; Haugwitz, U.; Wasner, M.; Hauss, J.; Engeland, K.; Wittekind, C. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int. J. Cancer, 2000, 89(4), 350-355.
287. Nakai, S.; Masaki, T.; Shiratori, Y.; Ohgi, T.; Morishita, A.; Kurokohchi, K.; Watanabe, S.; Kuriyama, S. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int. J. Oncol., 2002, 20(4), 769-775.
288. Okabe, H.; Satoh, S.; Kato, T.; Kitahara, O.; Yanagawa, R.; Yamaoka, Y.; Tsunoda, T.; Furukawa, Y.; Nakamura, Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res., 2001, 61(5), 2129-37.
289. Delpuech, O.; Trabut, J. B.; Carnot, F.; Feuillard, J.; Brechot, C.; Kremsdorf, D. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene, 2002, 21(18), 2926-2937.
290. Iizuka, N.; Oka, M.; Yamada-Okabe, H.; Mori, N.; Tamesa, T.; Okada, T.; Takemoto, N.; Tangoku, A.; Hamada, K.; Nakayama, H.; Miyamoto, T.; Uchimura, S.; Hamamoto, Y. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res., 2002, 62(14), 3939-3944.
291. Smith, M. W.; Yue, Z. N.; Geiss, G. K.; Sadovnikova, N. Y.; Carter, V. S.; Boix, L.; Lazaro, C. A.; Rosenberg, G. B.; Bumgarner, R. E.; Fausto, N.; Bruix, J.; Katze, M. G. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res., 2003, 63(4), 859-864.
292. Ye, Q. H.; Qin, L. X.; Forgues, M.; He, P.; Kim, J. W.; Peng, A. C.; Simon, R.; Li, Y.; Robles, A. I.; Chen, Y.; Ma, Z. C.; Wu, Z. Q.; Ye, S. L.; Liu, Y. K.; Tang, Z. Y.; Wang, X. W. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med., 2003, 9(4), 416-423.
293. Wang, S. M.; Ooi, L. L.; Hui, K. M. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin. Cancer Res., 2007, 13(21), 6275-6283.
294. Iizuka, N.; Oka, M.; Yamada-Okabe, H.; Nishida, M.; Maeda, Y.; Mori, N.; Takao, T.; Tamesa, T.; Tangoku, A.; Tabuchi, H.; Hamada, K.; Nakayama, H.; Ishitsuka, H.; Miyamoto, T.; Hirabayashi, A.; Uchimura, S.; Hamamoto, Y. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet, 2003, 361(9361), 923-929.
295. Kurokawa, Y.; Matoba, R.; Takemasa, I.; Nagano, H.; Dono, K.; Nakamori, S.; Umeshita, K.; Sakon, M.; Ueno, N.; Oba, S.; Ishii, S.; Kato, K.; Monden, M. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J. Hepatol., 2004, 41(2), 284-291.
296. Woo, H. G.; Park, E. S.; Cheon, J. H.; Kim, J. H.; Lee, J. S.; Park, B. J.; Kim, W.; Park, S. C.; Chung, Y. J.; Kim, B. G.; Yoon, J. H.; Lee, H. S.; Kim, C. Y.; Yi, N. J.; Suh, K. S.; Lee, K. U.; Chu, I. S.; Roskams, T.; Thorgeirsson, S. S.; Kim, Y. J. Gene expressionbased recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res., 2008, 14(7), 2056-2064.
297. Lee, J. D.; Yun, M.; Lee, J. M.; Choi, Y.; Choi, Y. H.; Kim, J. S.; Kim, S. J.; Kim, K. S.; Yang, W. I.; Park, Y. N.; Han, K. H.; Lee, W. J.; Yoo, N.; Lim, S. M.; Park, J. H. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18Ffluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging, 2004, 31(12), 1621-30.
298. Li, W.; Xie, L.; He, X.; Li, J.; Tu, K.; Wei, L.; Wu, J.; Guo, Y.; Ma, X.; Zhang, P.; Pan, Z.; Hu, X.; Zhao, Y.; Xie, H.; Jiang, G.; Chen, T.; Wang, J.; Zheng, S.; Cheng, J.; Wan, D.; Yang, S.; Li, Y.; Gu, J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer, 2008, 123(7), 1616-1622.
299. Zhang, J.; Yang, Y.; Yang, T.; Liu, Y.; Li, A.; Fu, S.; Wu, M.; Pan, Z.; Zhou, W. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer, 2010, 103(8), 1215-1220.
300. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; Li, Q.; Li, X.; Wang, W.; Wang, J.; Jiang, X.; Xiang, Y.; Xu, C.; Zheng, P.; Zhang, J.; Li, R.; Zhang, H.; Shang, X.; Gong, T.; Ning, G.; Zen, K.; Zhang, C. Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 2008, 18(10), 997-1006.
301. Lawrie, C. H.; Gal, S.; Dunlop, H. M.; Pushkaran, B.; Liggins, A. P.; Pulford, K.; Banham, A. H.; Pezzella, F.; Boultwood, J.; Wainscoat, J. S.; Hatton, C. S.; Harris, A. L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol., 2008, 141(5), 672-675.
302. Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K. C.; Allen, A.; Lin, D. W.; Urban, N.; Drescher, C. W.; Knudsen, B. S.; Stirewalt, D. L.; Gentleman, R.; Vessella, R. L.; Nelson, P. S.; Martin, D. B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10513-10518.
303. Wang, K.; Zhang, S.; Marzolf, B.; Troisch, P.; Brightman, A.; Hu, Z.; Hood, L. E.; Galas, D. J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A, 2009, 106(11), 4402-7.
304. Zhang, Y.; Jia, Y.; Zheng, R.; Guo, Y.; Wang, Y.; Guo, H.; Fei, M.; Sun, S. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem., 2010, 56(12), 1830-1838.
305. Li, L. M.; Hu, Z. B.; Zhou, Z. X.; Chen, X.; Liu, F. Y.; Zhang, J. F.; Shen, H. B.; Zhang, C. Y.; Zen, K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res., 2010, 70(23), 9798-9807.
306. Gui, J.; Tian, Y.; Wen, X.; Zhang, W.; Zhang, P.; Gao, J.; Run, W.; Tian, L.; Jia, X.; Gao, Y. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond), 2011, 120(5), 183-93.
307. Xu, J.; Wu, C.; Che, X.; Wang, L.; Yu, D.; Zhang, T.; Huang, L.; Li, H.; Tan, W.; Wang, C.; Lin, D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog., 2011, 50(2), 136-42.
308. Qu, K. Z.; Zhang, K.; Li, H.; Afdhal, N. H.; Albitar, M. Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma. J. Clin. Gastroenterol., 2011.
309. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res., 2006, 66(24), 11851-11858.
310. Llovet, J. M.; Bruix, J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol., 2008, 48 Suppl 1,S20-S37.
311. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
312. Zender, L.; Hutker, S.; Liedtke, C.; Tillmann, H. L.; Zender, S.; Mundt, B.; Waltemathe, M.; Gosling, T.; Flemming, P.; Malek, N. P.; Trautwein, C.; Manns, M. P.; Kuhnel, F.; Kubicka, S. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA, 2003, 100(13), 7797-7802.
313. Song, E.; Lee, S. K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 2003, 9(3), 347-351.
314. Cimmino, A.; Calin, G. A.; Fabbri, M.; Iorio, M. V.; Ferracin, M.; Shimizu, M.; Wojcik, S. E.; Aqeilan, R. I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C. G.; Kipps, T. J.; Negrini, M.; Croce, C. M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA, 2005, 102(39), 13944-13949.
315. Fontana, L.; Fiori, M. E.; Albini, S.; Cifaldi, L.; Giovinazzi, S.; Forloni, M.; Boldrini, R.; Donfrancesco, A.; Federici, V.; Giacomini, P.; Peschle, C.; Fruci, D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One, 2008, 3(5), e2236.
316. Mercatelli, N.; Coppola, V.; Bonci, D.; Miele, F.; Costantini, A.; Guadagnoli, M.; Bonanno, E.; Muto, G.; Frajese, G. V.; De Maria, R.; Spagnoli, L. G.; Farace, M. G.; Ciafre, S. A. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One, 2008, 3(12), e4029.
317. Ma, L.; Reinhardt, F.; Pan, E.; Soutschek, J.; Bhat, B.; Marcusson, E. G.; Teruya-Feldstein, J.; Bell, G. W.; Weinberg, R. A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol., 2010, 28(4), 341-347.
318. Zhang, C.; Kang, C.; You, Y.; Pu, P.; Yang, W.; Zhao, P.; Wang, G.; Zhang, A.; Jia, Z.; Han, L.; Jiang, H. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol, 2009, 34(6), 1653-60.
319. Ma, S.; Tang, K. H.; Chan, Y. P.; Lee, T. K.; Kwan, P. S.; Castilho, A.; Ng, I.; Man, K.; Wong, N.; To, K. F.; Zheng, B. J.; Lai, P. B.; Lo, C. M.; Chan, K. W.; Guan, X. Y. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell, 2010, 7(6), 694-707.
320. Sachdeva, M.; Mo, Y. Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res, 2010, 70(1), 378-87.
321. Gregersen, L. H.; Jacobsen, A. B.; Frankel, L. B.; Wen, J.; Krogh, A.; Lund, A. H. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One, 2010, 5(1), e8836.
322. Chiyomaru, T.; Enokida, H.; Tatarano, S.; Kawahara, K.; Uchida, Y.; Nishiyama, K.; Fujimura, L.; Kikkawa, N.; Seki, N.; Nakagawa, M. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer, 2010, 102(5), 883-891.
323. Migliore, C.; Petrelli, A.; Ghiso, E.; Corso, S.; Capparuccia, L.; Eramo, A.; Comoglio, P. M.; Giordano, S. MicroRNAs impair MET-mediated invasive growth. Cancer Res, 2008, 68(24), 10128-36.
324. Garzia, L.; Andolfo, I.; Cusanelli, E.; Marino, N.; Petrosino, G.; De Martino, D.; Esposito, V.; Galeone, A.; Navas, L.; Esposito, S.; Gargiulo, S.; Fattet, S.; Donofrio, V.; Cinalli, G.; Brunetti, A.; Vecchio, L. D.; Northcott, P. A.; Delattre, O.; Taylor, M. D.; Iolascon, A.; Zollo, M. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One, 2009, 4(3), e4998.
325. Chen, R.; Alvero, A. B.; Silasi, D. A.; Kelly, M. G.; Fest, S.; Visintin, I.; Leiser, A.; Schwartz, P. E.; Rutherford, T.; Mor, G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene, 2008, 27(34), 4712-4723.
326. Chao, A.; Tsai, C. L.; Wei, P. C.; Hsueh, S.; Chao, A. S.; Wang, C. J.; Tsai, C. N.; Lee, Y. S.; Wang, T. H.; Lai, C. H. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett., 2010, 291(1), 99-107.
327. Hossain, A.; Kuo, M. T.; Saunders, G. F. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol, 2006, 26(21), 8191-8201.
328. Shan, S. W.; Lee, D. Y.; Deng, Z.; Shatseva, T.; Jeyapalan, Z.; Du, W. W.; Zhang, Y.; Xuan, J. W.; Yee, S. P.; Siragam, V.; Yang, B. B. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat. Cell Biol., 2009, 11(8), 1031-1038.
329. Tan, L. P.; Seinen, E.; Duns, G.; de Jong, D.; Sibon, O. C.; Poppema, S.; Kroesen, B. J.; Kok, K.; van den Berg, A. A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res., 2009, 37(20), e137.
330. Wang, Q.; Li, Y. C.; Wang, J.; Kong, J.; Qi, Y.; Quigg, R. J.; Li, X. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc. Natl. Acad. Sci. USA, 2008, 105(8), 2889-2894.
331. Loven, J.; Zinin, N.; Wahlstrom, T.; Muller, I.; Brodin, P.; Fredlund, E.; Ribacke, U.; Pivarcsi, A.; Pahlman, S.; Henriksson, M. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc. Natl. Acad. Sci. USA, 2010, 107(4), 1553-1558.
332. Ohgawara, T.; Kubota, S.; Kawaki, H.; Kondo, S.; Eguchi, T.; Kurio, N.; Aoyama, E.; Sasaki, A.; Takigawa, M. Regulation of chondrocytic phenotype by micro RNA 18a: involvement of Ccn2/Ctgf as a major target gene. FEBS Lett., 2009, 583(6), 1006-1010.
333. Vreugdenhil, E.; Verissimo, C. S.; Mariman, R.; Kamphorst, J. T.; Barbosa, J. S.; Zweers, T.; Champagne, D. L.; Schouten, T.; Meijer, O. C.; de Kloet, E. R.; Fitzsimons, C. P. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology, 2009, 150(5), 2220-2228.
334. Liu, M.; Wu, H.; Liu, T.; Li, Y.; Wang, F.; Wan, H.; Li, X.; Tang, H. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res, 2009, 19(7), 828-837.
335. Papagiannakopoulos, T.; Shapiro, A.; Kosik, K. S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res., 2008, 68(19), 8164-8172.
336. Sayed, D.; Rane, S.; Lypowy, J.; He, M.; Chen, I. Y.; Vashistha, H.; Yan, L.; Malhotra, A.; Vatner, D.; Abdellatif, M. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell, 2008, 19(8), 3272-3282.
337. Di Leva, G.; Gasparini, P.; Piovan, C.; Ngankeu, A.; Garofalo, M.; Taccioli, C.; Iorio, M. V.; Li, M.; Volinia, S.; Alder, H.; Nakamura, T.; Nuovo, G.; Liu, Y.; Nephew, K. P.; Croce, C. M. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J. Natl. Cancer Inst., 2010, 102(10), 706-721.
338. Frenquelli, M.; Muzio, M.; Scielzo, C.; Fazi, C.; Scarfo, L.; Rossi, C.; Ferrari, G.; Ghia, P.; Caligaris-Cappio, F. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood, 2010, 115(19), 3949-3959.
339. Hu, G.; Gong, A. Y.; Liu, J.; Zhou, R.; Deng, C.; Chen, X. M. miR-221 suppresses ICAM-1 translation and regulates interferongamma- induced ICAM-1 expression in human cholangiocytes. Am J. Physiol. Gastrointest Liver Physiol., 2010, 298(4), G542-G550.
340. Hussein, K.; Theophile, K.; Busche, G.; Schlegelberger, B.; Gohring, G.; Kreipe, H.; Bock, O. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk. Res., 2010, 34(3), 328-334.
341. Igoucheva, O.; Alexeev, V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem. Biophys. Res. Commun., 2009, 379(3), 790-794.
342. Miller, T. E.; Ghoshal, K.; Ramaswamy, B.; Roy, S.; Datta, J.; Shapiro, C. L.; Jacob, S.; Majumder, S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem., 2008, 283(44), 29897-29903.
343. Visone, R.; Russo, L.; Pallante, P.; De Martino, I.; Ferraro, A.; Leone, V.; Borbone, E.; Petrocca, F.; Alder, H.; Croce, C. M.; Fusco, A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer, 2007, 14(3), 791-798.
344. Zhao, J. J.; Lin, J.; Yang, H.; Kong, W.; He, L.; Ma, X.; Coppola, D.; Cheng, J. Q. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem., 2008, 283(45), 31079-31086.
345. Mees, S. T.; Mardin, W. A.; Sielker, S.; Willscher, E.; Senninger, N.; Schleicher, C.; Colombo-Benkmann, M.; Haier, J. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann. Surg. Oncol., 2009, 16(8), 2339-2350.
346. White, N. M.; Bui, A.; Mejia-Guerrero, S.; Chao, J.; Soosaipillai, A.; Youssef, Y.; Mankaruos, M.; Honey, R. J.; Stewart, R.; Pace, K. T.; Sugar, L.; Diamandis, E. P.; Dore, J.; Yousef, G. M. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol. Chem., 2010, 391(4), 411-423.
347. Yao, G.; Yin, M.; Lian, J.; Tian, H.; Liu, L.; Li, X.; Sun, F. MicroRNA-224 is involved in transforming growth factor-betamediated mouse granulosa cell proliferation and granulosa cell function by targeting Smad4. Mol Endocrinol, 2010, 24(3), 540-51.
348. Zhu, S.; Sachdeva, M.; Wu, F.; Lu, Z.; Mo, Y. Y. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene, 2010, 29(12), 1763-172.
349. Voorhoeve, P. M.; le Sage, C.; Schrier, M.; Gillis, A. J.; Stoop, H.; Nagel, R.; Liu, Y. P.; van Duijse, J.; Drost, J.; Griekspoor, A.; Zlotorynski, E.; Yabuta, N.; De Vita, G.; Nojima, H.; Looijenga, L. H.; Agami, R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell, 2006, 124(6), 1169-1181.
350. Viswanathan, S. R.; Powers, J. T.; Einhorn, W.; Hoshida, Y.; Ng, T. L.; Toffanin, S.; O'Sullivan, M.; Lu, J.; Phillips, L. A.; Lockhart, V. L.; Shah, S. P.; Tanwar, P. S.; Mermel, C. H.; Beroukhim, R.; Azam, M.; Teixeira, J.; Meyerson, M.; Hughes, T. P.; Llovet, J. M.; Radich, J.; Mullighan, C. G.; Golub, T. R.; Sorensen, P. H.; Daley, G. Q. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet., 2009, 41(7), 843-848.